ORCHID: A phase II study of olaparib in metastatic renal cell carcinoma patients harborIng a BAP1 or other DNA repair gene mutations

This is an interim analysis of the ORCHID study, which is investigating the clinical activity of single agent olaparib in patients with advanced RCC harboring BAP1 mutant lines and other DNA damage repair genes alterations. ORCHID is the first study investigating single agent PARPi in RCC with the interim trial analysis indicating promising activity of olaparib in advanced RCC patitions with BAP1 mutations, including one patient with deep PR.